Our latest press releases, media appearances and news commentary.
New drug discovery research to tackle the growing health epidemic of antimicrobial resistance will soon be underway.
UK pharma R&D productivity is at an all-time low, warns our CEO Chris Molloy.
Peter will be joining their board this year along with Emilio Diez Monedero and Severine Tamas-Lhoustau.
The Medicines Discovery Catapult and BioIndustry Association call on the R&D community to address five themes to help boost productivity.
Our Chief Executive Officer, Chris Molloy, explores how Medicines Discovery Catapult is supporting the community to realise the future of drug discovery.
Mark is Chief Business and Strategy Officer at the Medicines Discovery Catapult.
The amount of capital invested alongside CVC into UK companies increased six-fold between 2010 and 2015.
Chris Molloy responds to the Government’s Industrial Strategy White Paper.
Statement from Medicines Discovery Catapult.
Watch our new video introducing the Catapult programme, its centres and crucial work.
See how we can help support you with your next drug discovery project.
Speak to us